What is the recommended timeframe for a 67-year-old patient with significantly elevated faecal calprotectin levels, indicating severe intestinal inflammation, to be seen by gastroenterology for an endoscopy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timeframe for Gastroenterology Referral with Significantly Elevated Faecal Calprotectin

A 67-year-old patient with significantly elevated faecal calprotectin indicating severe intestinal inflammation should be seen by gastroenterology urgently, ideally within 2 weeks, with endoscopy performed as soon as feasible thereafter. 1, 2

Rationale for Urgent Referral

  • Faecal calprotectin >250 μg/g strongly indicates active inflammatory disease requiring immediate investigation, and levels substantially above this threshold (as implied by "significantly elevated" in a symptomatic patient) suggest severe intestinal inflammation with a 95.4% likelihood of true moderate-to-severe endoscopic inflammation. 2, 3

  • Early endoscopy within 7-30 days is associated with significantly shorter symptom duration (19 vs 47 days) and reduced steroid treatment duration compared to delayed evaluation, making timely referral critical for patient outcomes. 3

  • The British Society of Gastroenterology recommends that patients with calprotectin levels >250 μg/g warrant urgent referral to gastroenterology for endoscopic assessment. 1

Clinical Context Determines Exact Timing

If Moderate-to-Severe Symptoms Present:

  • Urgent referral within 1-2 weeks is appropriate, as the combination of significant symptoms with markedly elevated calprotectin has only a 4.6% false positive rate for moderate-to-severe endoscopic inflammation. 2, 3

  • The American Gastroenterological Association suggests that in patients with moderate to severe symptoms and calprotectin >150 μg/g, treatment adjustment can proceed without initial endoscopy, though endoscopy remains essential for establishing diagnosis in treatment-naïve patients. 4

If Mild or No Symptoms:

  • Referral within 2-4 weeks is reasonable, though endoscopic assessment should still be prioritized over empiric treatment adjustment in patients with mild symptoms and elevated biomarkers. 4

  • In asymptomatic patients with known IBD and calprotectin >150 μg/g, there is a 22.4% false positive rate, but endoscopic evaluation should still be considered given the patient's age and need for definitive diagnosis. 2

Pre-Endoscopy Workup to Expedite Care

While awaiting gastroenterology appointment, the following should be completed:

  • Stool cultures and C. difficile testing to exclude infectious causes, as enteric infections can markedly elevate calprotectin. 3

  • Complete blood count to assess for anaemia and thrombocytosis indicating inflammation. 1

  • C-reactive protein (CRP) as a complementary inflammatory marker, though 20% of active Crohn's patients may have normal CRP. 1

  • Coeliac serology (tissue transglutaminase antibodies) to exclude coeliac disease. 1, 3

  • Urea and electrolytes to assess for dehydration and electrolyte abnormalities. 1

Critical Caveats

  • If alarm features are present (rectal bleeding with abdominal pain, change in bowel habit, weight loss, or iron-deficiency anaemia), referral via a suspected cancer pathway is required regardless of calprotectin level, with target assessment within 2 weeks. 1

  • NSAID use within the past 6 weeks can falsely elevate calprotectin, and this should be documented in the referral, though it should not delay urgent evaluation given the clinical context. 1

  • Faecal calprotectin is not specific for IBD and can be elevated in infectious gastroenteritis, colorectal cancer, microscopic colitis, and other inflammatory conditions, making endoscopic confirmation essential. 1, 2

Expected Endoscopic Approach

  • Complete colonoscopy with terminal ileum intubation is preferred over flexible sigmoidoscopy to assess the full extent of disease. 3

  • Multiple biopsies should be obtained even from normal-appearing mucosa to establish histologic diagnosis. 3

  • If Crohn's disease is suspected based on initial findings, cross-sectional imaging (MR enterography or CT enterography) may be needed to evaluate small bowel involvement. 1

References

Guideline

Calprotectin as a Biomarker for Intestinal Inflammation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fecal Calprotectin Guidance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Severe Active Intestinal Inflammation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.